Literature DB >> 28115808

The Effects of Ivabradine on Left Ventricular Synchronization and Tei Index in Patients with Systolic Heart Failure.

Fatma Hizal Erdem1, Serkan Ozturk1, Selçuk Öztürk1, Alim Erdem1, Selim Ayhan1, Mustafa Öztürk2, İbrahim Dönmez1, Davut Baltacı3, Mehmet Yazıcı1.   

Abstract

BACKGROUND: The aim of our study was to evaluate in stable outpatients with systolic heart failure (HF) the 3 months effect of ivabradine on LV synchronization and Tei index in stable outpatients with systolic HF.
METHODS: We evaluated prospectively 40 (30 males, 10 females) patients with HF. All patients were evaluated before and after treatment by transthoracic M mode, two dimensional (2D), pulsed-wave (PW), continuous wave (CW), color flow and tissue Doppler imaging (TDI) and tissue synchronization imaging (TSI). Standard deviation of Ts of the 12 LV segments (Ts-SD-12) is the most widely used parameter of intra-LV asynchrony.
RESULTS: Thirty men and 10 women with mean ± SD age of 64.7 ± 9.9 years were included in this study. Most of the patients benefitted from some degree of clinical improvement, 12/16 (75.0%) from NYHA III to II and 18/24 (75.0%) from II to I, respectively. Resting heart rate was significantly reduced after ivabradine treatment (84.3 ± 11.4 vs. 66.5 ± 11.5 bpm, p < 0.001). E/E' and Tei index were significantly changed after ivabradine treatment (17.3 ± 9.0 vs. 14.8 ± 7.1, p = 0.02 and 0.86 ± 0.74 vs. 0.81 ± 0.69, p = 0.02). Intra-LV synchrony parameters Ts-SD-12 and Ts-12 were significantly reduced after ivabradine (46.8 ± 13.6 vs. 42.7 ± 13.1, p = 0.01 and 142.5 ± 44.0 vs. 128.5 ± 45.2, p = 0.009).
CONCLUSIONS: The present study demonstrated that adding ivabradine to the standard therapy reduced HR and significantly improved LV ventricular asynchrony and Tei index in systolic HF patients.

Entities:  

Keywords:  Heart failure; Ivabradine; Left ventricular function

Year:  2017        PMID: 28115808      PMCID: PMC5241437          DOI: 10.6515/acs20160205b

Source DB:  PubMed          Journal:  Acta Cardiol Sin        ISSN: 1011-6842            Impact factor:   2.672


  27 in total

1.  Changes in diastolic time with various pharmacologic agents: implication for myocardial perfusion.

Authors:  H Boudoulas; S E Rittgers; R P Lewis; C V Leier; A M Weissler
Journal:  Circulation       Date:  1979-07       Impact factor: 29.690

2.  Evaluation of left ventricular systolic asynchrony in patients with subclinical hypothyroidism.

Authors:  Serkan Ozturk; Aytekin Alcelik; Mehmet Ozyasar; Oguz Dikbas; Selim Ayhan; Fatih Ozlu; Alim Erdem; Mehmet Tosun; Davut Baltaci; Mehmet Yazici
Journal:  Cardiol J       Date:  2012       Impact factor: 2.737

3.  Effects of aldosterone receptor blockade in patients with mild-moderate heart failure taking a beta-blocker.

Authors:  Colin Berry; Niamh F Murphy; Niamh Murphy; Giuseppe De Vito; Stuart Galloway; Alison Seed; Carol Fisher; Naveed Sattar; Patrick Vallance; W Sewart Hillis; John McMurray
Journal:  Eur J Heart Fail       Date:  2006-11-27       Impact factor: 15.534

Review 4.  Clinical Assessment and Implication of Left Ventricular Mechanical Dyssynchrony in Patients with Heart Failure.

Authors:  Yi-Hsin Chan; Chun-Li Wang; Chi-Tai Kuo; Yung-Hsin Yeh; Chia-Tung Wu; Lung-Sheng Wu
Journal:  Acta Cardiol Sin       Date:  2013-11       Impact factor: 2.672

5.  Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT).

Authors:  Karl Swedberg; Michel Komajda; Michael Böhm; Jeffrey S Borer; Ian Ford; Luigi Tavazzi
Journal:  Eur J Heart Fail       Date:  2009-11-05       Impact factor: 15.534

Review 6.  Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease.

Authors:  Dario DiFrancesco; John A Camm
Journal:  Drugs       Date:  2004       Impact factor: 9.546

7.  Effect of beta-blockade and ACE inhibition on B-type natriuretic peptides in stable patients with systolic heart failure.

Authors:  Jens Rosenberg; Finn Gustafsson; Willem J Remme; Günter A J Riegger; Per Rossen Hildebrandt
Journal:  Cardiovasc Drugs Ther       Date:  2008-02-29       Impact factor: 3.727

8.  Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial.

Authors:  Kim Fox; Ian Ford; P Gabriel Steg; Michal Tendera; Michele Robertson; Roberto Ferrari
Journal:  Lancet       Date:  2008-08-29       Impact factor: 79.321

9.  Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure.

Authors:  Paul Mulder; Stephane Barbier; Abdeslam Chagraoui; Vincent Richard; Jean Paul Henry; Françoise Lallemand; Sylvanie Renet; Guy Lerebours; Florence Mahlberg-Gaudin; Christian Thuillez
Journal:  Circulation       Date:  2004-02-23       Impact factor: 29.690

10.  Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy.

Authors:  Jean-Claude Tardif; Eileen O'Meara; Michel Komajda; Michael Böhm; Jeffrey S Borer; Ian Ford; Luigi Tavazzi; Karl Swedberg
Journal:  Eur Heart J       Date:  2011-08-29       Impact factor: 29.983

View more
  3 in total

1.  [Left ventricular Tei-index for evaluation of cardiac function in hypertensive patients with left ventricular hypertrophy after radiochemotherapy].

Authors:  Zou-Qin Huang; Tao Li
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-06-20

2.  Evaluation of ivabradine in left ventricular dyssynchrony and reverse remodeling in patients with chronic heart failure.

Authors:  Korhan Soylu; Idris Bugra Cerik; Gokhan Aksan; Gokay Nar; Murat Meric
Journal:  J Arrhythm       Date:  2020-07-05

3.  Effect of Heart Rate-Oriented Therapy on Diastolic Functions in Patients with Heart Failure with Reduced Ejection Fraction.

Authors:  Sedat Taş; Ümmü Taş; Ebru Özpelit; Efe Edem; Bahri Akdeniz
Journal:  Acta Cardiol Sin       Date:  2018-05       Impact factor: 2.672

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.